# A Pharmacokinetic Study to Evaluate the Effect of Antacids on Raltegravir (MK-0518) in HIV-Infected Participants (MK-0518-247)

> **NCT01622673** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 27 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Raltegravir
- **DRUG:** TUMS® Ultra Strength
- **DRUG:** MINTOX® Maximum Strength

## Key facts

- **NCT ID:** NCT01622673
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2017-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01622673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01622673, "A Pharmacokinetic Study to Evaluate the Effect of Antacids on Raltegravir (MK-0518) in HIV-Infected Participants (MK-0518-247)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01622673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*